Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

Swedish (OMX) Biotech Industry Analysis

UpdatedAug 09, 2025
DataAggregated Company Financials
Companies54
  • 7D1.4%
  • 3M-1.9%
  • 1Y-7.2%
  • YTDn/a

In the last week, the Biotech industry is up 1.4%, with Swedish Orphan Biovitrum up 3.2%. In contrast, the industry has lost 7.2% in the last 12 months. As for the next few years, earnings are expected to grow by 25% per annum.

Industry Valuation and Performance

Has the Swedish Biotech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 09 Aug 2025SEK 186.8bSEK 35.9bSEK 2.8b27.4x67x5.2x
Mon, 07 Jul 2025SEK 187.5bSEK 35.2bSEK 2.3b29.9x81.6x5.3x
Wed, 04 Jun 2025SEK 191.0bSEK 35.2bSEK 2.2b29.4x86.2x5.4x
Fri, 02 May 2025SEK 190.7bSEK 34.0bSEK 835.0m29.5x228.3x5.6x
Sun, 30 Mar 2025SEK 188.5bSEK 33.7bSEK 725.1m31.1x260x5.6x
Tue, 25 Feb 2025SEK 209.9bSEK 33.3bSEK 505.6m44.5x415.1x6.3x
Thu, 23 Jan 2025SEK 224.0bSEK 33.0b-SEK 4,418,211,832.77153.2x-50.7x6.8x
Sat, 21 Dec 2024SEK 214.9bSEK 33.0b-SEK 4,422,936,557.01155.2x-48.6x6.5x
Mon, 18 Nov 2024SEK 206.7bSEK 33.0b-SEK 4,533,339,044.08144.5x-45.6x6.3x
Wed, 16 Oct 2024SEK 206.9bSEK 31.4b-SEK 5,535,707,666.3947.4x-37.4x6.6x
Fri, 13 Sep 2024SEK 216.9bSEK 31.5b-SEK 5,528,218,182.9651.3x-39.2x6.9x
Sun, 11 Aug 2024SEK 195.0bSEK 31.4b-SEK 5,206,863,894.0344.5x-37.5x6.2x
Tue, 09 Jul 2024SEK 196.2bSEK 30.6b-SEK 5,524,042,948.5539.5x-35.5x6.4x
Thu, 06 Jun 2024SEK 199.4bSEK 30.6b-SEK 5,384,866,771.0340x-37x6.5x
Sat, 04 May 2024SEK 184.8bSEK 31.0b-SEK 5,451,959,822.3550.4x-33.9x6x
Mon, 01 Apr 2024SEK 185.5bSEK 29.8b-SEK 5,642,366,401.1160.5x-32.9x6.2x
Wed, 28 Feb 2024SEK 177.3bSEK 29.8b-SEK 5,596,556,849.3554.2x-31.7x6x
Fri, 26 Jan 2024SEK 188.4bSEK 28.7b-SEK 1,200,321,243.0061.4x-157x6.6x
Sun, 24 Dec 2023SEK 181.8bSEK 28.7b-SEK 1,195,731,362.0060.6x-152x6.3x
Tue, 21 Nov 2023SEK 168.0bSEK 28.7b-SEK 1,186,830,677.0054.9x-141.6x5.9x
Thu, 19 Oct 2023SEK 152.7bSEK 27.4b-SEK 1,977,226,718.0048x-77.2x5.6x
Sat, 16 Sep 2023SEK 153.7bSEK 27.4b-SEK 1,977,581,318.0047.7x-77.7x5.6x
Mon, 14 Aug 2023SEK 159.6bSEK 27.6b-SEK 1,574,638,943.0053.8x-101.4x5.8x
Wed, 12 Jul 2023SEK 159.9bSEK 26.4b-SEK 1,311,920,412.0045.3x-121.9x6.1x
Fri, 09 Jun 2023SEK 170.4bSEK 26.4b-SEK 1,234,997,179.0046.9x-138x6.5x
Sun, 07 May 2023SEK 179.4bSEK 26.4b-SEK 1,189,603,007.0046.2x-150.8x6.8x
Tue, 04 Apr 2023SEK 165.0bSEK 25.4b-SEK 2,017,070,076.0037.1x-81.8x6.5x
Thu, 02 Mar 2023SEK 172.8bSEK 25.4b-SEK 2,036,932,084.0039.3x-84.8x6.8x
Sat, 28 Jan 2023SEK 175.8bSEK 23.8b-SEK 1,837,778,394.0031.2x-95.7x7.4x
Mon, 26 Dec 2022SEK 156.7bSEK 23.8b-SEK 1,842,897,823.0031.4x-85x6.6x
Wed, 23 Nov 2022SEK 156.0bSEK 23.8b-SEK 1,731,805,814.0032.1x-90.1x6.5x
Fri, 21 Oct 2022SEK 146.9bSEK 22.9b-SEK 3,333,494,714.0029.6x-44.1x6.4x
Sun, 18 Sep 2022SEK 149.0bSEK 22.9b-SEK 3,249,190,732.0032.2x-45.9x6.5x
Tue, 16 Aug 2022SEK 171.3bSEK 22.6b-SEK 3,543,308,519.0035x-48.4x7.6x
Price to Earnings Ratio

-48.4x


Total Market Cap: SEK 171.3bTotal Earnings: -SEK 3,543,308,519.00Total Revenue: SEK 22.6bTotal Market Cap vs Earnings and Revenue0%0%0%
Swedish Biotech Industry Price to Earnings3Y Average -39.1x202320242025
Current Industry PE
  • Investors are optimistic on the Swedish Biotechnology industry, and appear confident in long term growth rates.
  • The industry is trading at a PE ratio of 67.0x which is higher than its 3-year average PE of -39.1x.
  • The 3-year average PS ratio of 6.3x is higher than the industry's current PS ratio of 5.2x.
Past Earnings Growth
  • Total earnings for the Biotechnology industry have gone up over the last three years, and the industry is now profitable. Revenues have grown 17% per year.
  • This means that more sales are being generated by the industry overall, and subsequently profits are increasing too.

Industry Comparison

How does Swedish Biotech compare with similar industries?

SE Market2.43%
Healthcare-0.92%
Biotech1.39%
Biotech1.39%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
SOBI Swedish Orphan BiovitrumSEK 272.803.2%
+SEK 2.9b		-2.0%PE21.5x
BIOA B BioArcticSEK 217.403.9%
+SEK 726.0m		37.9%PE21.3x
VICO Vicore Pharma HoldingSEK 11.6030.8%
+SEK 640.5m		-32.2%PS454x
HNSA Hansa BiopharmaSEK 30.386.7%
+SEK 161.1m		-21.9%PS13.1x
EGTX Egetis TherapeuticsSEK 5.787.6%
+SEK 147.3m		0.3%PS44.5x

Latest News

HNSA
SEK 30.38
Hansa Biopharma
7D
6.7%
1Y
-21.9%
SOBI
SEK 272.80
Swedish Orphan Biovitrum
7D
3.2%
1Y
-2.0%

We Think Swedish Orphan Biovitrum (STO:SOBI) Can Stay On Top Of Its Debt

Aug 04
We Think Swedish Orphan Biovitrum (STO:SOBI) Can Stay On Top Of Its Debt
BONEX
SEK 310.80
Bonesupport Holding
7D
-3.9%
1Y
10.8%
HAMLET B
SEK 4.20
Hamlet BioPharma
7D
14.3%
1Y
1.4%
VITR
SEK 135.50
Vitrolife
7D
-4.0%
1Y
-38.4%
author-image

US IVF Treatment Rebound And APAC Reimbursements Will Drive Recovery

Recovery in IVF procedure volume and expansion in key regions will drive organic revenue growth and margin improvement as market conditions stabilize.
ONCO
SEK 4.91
Oncopeptides
7D
-14.8%
1Y
102.9%

A Look At The Fair Value Of Oncopeptides AB (publ) (STO:ONCO)

Jul 28
A Look At The Fair Value Of Oncopeptides AB (publ) (STO:ONCO)
IMMU
SEK 7.96
Mendus
7D
-15.9%
1Y
4.7%
BIOG B
SEK 94.45
BioGaia
7D
-1.0%
1Y
-25.7%
BIOA B
SEK 217.40
BioArctic
7D
3.9%
1Y
37.9%
EGTX
SEK 5.78
Egetis Therapeutics
7D
7.6%
1Y
0.3%
CRNO B
SEK 9.13
Cereno Scientific
7D
-1.7%
1Y
44.1%
SYNACT
SEK 19.26
SynAct Pharma
7D
-8.3%
1Y
125.4%
DMYD B
SEK 11.48
Diamyd Medical
7D
7.1%
1Y
-39.6%
SANION
SEK 8.40
Saniona
7D
-8.1%
1Y
94.9%

Improved Revenues Required Before Saniona AB (publ) (STO:SANION) Stock's 37% Jump Looks Justified

Jun 19
Improved Revenues Required Before Saniona AB (publ) (STO:SANION) Stock's 37% Jump Looks Justified
BINV
SEK 39.70
BioInvent International
7D
4.5%
1Y
1.9%
VICO
SEK 11.60
Vicore Pharma Holding
7D
30.8%
1Y
-32.2%